VSTM

Verastem’s TARGET D 101 trial showed strong activity of VS‑7375 in KRAS G12D‑mutated pancreatic, colorectal and lung cancers, with good safety and high response rates at 900 mg daily. The company is working with the FDA on a first‑line pancreatic Phase 3 design.

BOSTON, October 22, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its third quarter 2026 financial results and business updates on Thursday, November 5, 2026, at 4:30 pm ET.

Incyte highlighted ESMO 2026 findings that KRAS G12D, INCA33890 and CDK2 combinations show promise in solid tumors, ahead of the Jakafi line of evidence.

BTIG analyst Jeet Mukherjee recommends buying Verastem and keeps a $24 price target.

Mizuho analyst Graig Suvannavejh rates Verastem as Outperform and raises the target price to $14 from $13.

Verastem’s share price jumped after releasing TARGET‑D 101 data and a $250 million equity raise, boosting short‑term returns.

Verastem reported a 50% confirmed overall response rate for VS‑7375 in second‑line metastatic pancreatic cancer at 900 mg daily, driving its best day in 11 months.

Healthcare stocks gained Thursday afternoon, with the NYSE Healthcare Index up 2.3%.